Cancer Immunotherapy

Endometrial (Uterine) Carcinoma

An immune checkpoint inhibitor is approved in combination with a targeted therapy to treat women who have advanced endometrial cancer that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), whose cancer has not been controlled by systemic therapy and who are not candidates for curative surgery or radiation therapy.

The uterus is a pear-shaped, hollow organ in the pelvis (see Female Reproductive Anatomy). In some patients, endometrial cancer may have MSI-H or dMMR seen on review of the tissue. These patients would be eligible for immunotherapy with immune checkpoint inhibitors.


PreviousNext